GRAFT-VERSUS-HOST-DISEASE
Clinical trials for GRAFT-VERSUS-HOST-DISEASE explained in plain language.
Never miss a new study
Get alerted when new GRAFT-VERSUS-HOST-DISEASE trials appear
Sign up with your email to follow new studies for GRAFT-VERSUS-HOST-DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a cancer drug stop transplant rejection in kids?
Disease control OngoingThis study tests whether adding the drug vorinostat to standard care can lower the chance of graft-versus-host disease (GVHD) in children, teens, and young adults getting a bone marrow or blood stem cell transplant for blood cancers. About 43 participants will receive vorinostat …
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 26, 2026 09:39 UTC
-
New combo aims to tame transplant complications in older blood cancer patients
Disease control OngoingThis study tests whether a lower-dose combination of two drugs (PTCy and ruxolitinib) can prevent graft-versus-host disease (GVHD) in older adults receiving a stem cell transplant for blood cancer. About 56 participants will receive the treatment and be monitored for survival wit…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 26, 2026 09:37 UTC
-
New drug combo aims to tame stem cell Transplant's worst side effect
Disease control OngoingThis study tests whether adding a drug called cyclophosphamide after a stem cell transplant can reduce the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers who are…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 09:36 UTC
-
Could a lower drug dose make stem cell transplants safer for blood cancer patients?
Disease control OngoingThis study looks at whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent complications like graft-versus-host disease (GVHD) while still controlling blood cancers. About 105 people aged 15-65 with leukemia, lymphoma, or multiple myelo…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:33 UTC
-
New hope for kids: drug combo may stop transplant rejection
Disease control OngoingThis study tests whether adding abatacept to standard medications can prevent graft-versus-host disease (GVHD) in 30 children and teens receiving stem cell transplants from unrelated donors for serious blood disorders. GVHD is a dangerous complication where donor cells attack the…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 09:29 UTC
-
New device could reduce deadly transplant complication in blood cancer patients
Disease control TerminatedThis study tests a device that filters out certain immune cells from donor blood before a stem cell transplant. The goal is to lower the risk of graft-versus-host disease, a serious complication where the donor cells attack the patient's body. About 50 adults with myelodysplastic…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE2 • Sponsor: Guenther Koehne • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Blood disorder drug safety tracked in long-term follow-up study
Disease control OngoingThis study checks the long-term safety of the drug ruxolitinib (given alone or with panobinostat) in people with certain blood or immune conditions like myelofibrosis, polycythemia vera, graft-versus-host disease, acute myeloid leukemia, or thalassemia. Participants had already b…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
Gut germs linked to transplant complication risk
Knowledge-focused OngoingThis study looks at how changes in gut bacteria and chemicals after a stem cell transplant might influence the development of graft-versus-host disease (GVHD), a serious complication. Researchers will collect stool and blood samples from 88 transplant recipients and their donors …
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla • Aim: Knowledge-focused
Last updated May 26, 2026 08:19 UTC